- Home
- NXB vs PRPO Comparison
NXB vs PRPO Comparison
Compare NXB & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXB | PRPO |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 42.0M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NXB | PRPO |
|---|---|---|
| Price | $1.88 | $27.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.2K | ★ 104.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,866,298.00 | $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 21.08 | ★ 29.77 |
| 52 Week Low | $1.79 | $14.04 |
| 52 Week High | $2.57 | $33.63 |
Technical Indicators
Market Signals| Indicator | NXB | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 73.26 |
| Support Level | $1.79 | $22.25 |
| Resistance Level | $2.32 | $33.63 |
| Average True Range (ATR) | 0.15 | 1.78 |
| MACD | -0.03 | 0.79 |
| Stochastic Oscillator | 2.30 | 95.44 |
Price Performance
Historical ComparisonAbout NXB NextBoat Inc. Common Stcok
NextBoat Inc focused on AI-powered technology platform designed to modernize and scale the world-wide pre-owned marine marketplace.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.